

Form PTO-1449 (modified)		Temp. Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CD	C169	Liang, <i>et al.</i> , "Cross-Species VEGF-Blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF," <i>J. Biol. Chem.</i> , www.jbc.org/cgi/doi/10.1074/jbc.org/M508199200 , published on-line on November 7, 2005.
↓	C170	Meyer, <i>et al.</i> , "A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1," <i>J. Biol. Chem.</i> , www.jbc.org/cgi/doi/10.1074/jbc.org/M506454200 , published on-line on November 14, 2005.

EXAMINER: *Cather Gere*

DATE CONSIDERED: *3/2/06*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Information Disclosure Statement — PTO-1449 (Modified)



Form PTO-1449 (modified)		Temp. Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A74	5,922,688	Jul. 13, 1999	Hung <i>et al.</i>	514	44	
cf							

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
cf	B22	EP 0 458 878	Sep. 4, 1996	EPO	A61K	39/00	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
cf	C168	Greenberg <i>et al.</i> , "A Clinical Trial of Antioxidant Vitamins to Prevent Colorectal Adenoma," <i>N. Engl. J. Med.</i> , 331:141-147, 1994.

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Information Disclosure Statement — PTO-1449 (Modified)



Form PTO-1449 (modified)

Temp. Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Thorpe *et al.*Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page*Other Art
See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A73	2005/0112126	May 26, 2005	Baca et al.	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cather Jones

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Information Disclosure Statement — PTO-1449 (Modified)



Form PTO-1449 (modified)

Temp. Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A72	5,725,856	March 10, 1998	Hudziak, et al.	424	130.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Catherine [Signature]

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See PageOther Art
See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A66	2003/0206899 A1	Nov. 06, 2003	Ferrara <i>et al.</i>	424	133.1	
	A67	2003/0203409	Oct. 30, 2003	Kim	435	7.1	
	A68	2003/0190317	Oct. 09, 2003	Baca <i>et al.</i>	424	142.1	
	A69	6,582,959	June 24, 2003	Kim	435	336	
	A70	2003/0086919	May 08, 2003	Rosenblum <i>et al.</i>	424	04.63	
	A71	2002/0098187	July 25, 2002	Ferrara <i>et al.</i>	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

8/2/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

3999.002587

10/738,404

List of Patents and Publications for Applicant's

Applicant

Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

December 17, 2003

Group:

1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Cf	C166	Bicknell and Harris, "Anticancer Strategies Involving the Vasculature: Vascular Targeting and the Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:399-407, 1992.
↓	C167	Bicknell and Harris, "Novel Growth Regulatory Factors and Tumour Angiogenesis," <i>Eur. J. Cancer</i> , 27(6):781-785, 1991.

EXAMINER:

Cathy Jones

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C165	Storkebaum <i>et al.</i> , "VEGF: Once Regarded as a Specific Angiogenic Factor, Now Implicated in Neuroprotection," <i>BioEssays</i> , 26:943-954, 2004.

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

3999.002587

Serial No.

10/738,404

Applicant

Thorpe and Brekken

Filing Date:

December 17, 2003

Group:

1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page 1

Other Art

See Pages 1-5

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CF	B19	EP 0 484 401 B1	September 11, 1996				
	B20	WO 91/02058	February 21, 1991				
	B21	WO 90/13649	November 15, 1990				

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CF	C99	Aiello, "Suppression of Retinal Neovascularization In Vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins," <i>Proc. Natl. Acad. USA</i> , 92:10457-10461, 1995.
	C100	Alvarez <i>et al.</i> , "Localization of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Human Glial Neoplasms," <i>Modern Pathology</i> , 5(3):303-307, 1992.
	C101	Auerbach, "Vascular Endothelial Cell Differentiation: Organ-Specificity and Selective Affinities as the Basis for Developing Anti-Cancer Strategies," <i>Int. J. Radiat. Biol.</i> , 60(1/2):1-10, 1991.
	C102	Baird <i>et al.</i> , "Immunoreactive Fibroblast Growth Factor (FGF) in a Transplantable Chondrosarcoma: Inhibition of Tumor Growth by Antibodies to FGF," <i>J. Cell. Biochem.</i> , 36:79-85, 1986.
	C103	Berse <i>et al.</i> , "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," <i>Molecular Biology Cell</i> , 3:211-220, 1992.
	C104	Berse <i>et al.</i> , "Vascular Permeability Factor Vascular Endothelial Cell Growth Factor Expression in Normal Tissues and in Tumors," <i>J. Cell Biol.</i> , 115(3 part 2):421a, Abstract No. 2443, 1991.

EXAMINER:

Catharine J. [Signature]

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CL	C105	Broadley <i>et al.</i> , "Monospecific Antibodies Implicate Basic Fibroblast Growth Factor in Normal Wound Repair," <i>Lab. Invest.</i> , 61(5):571-575, 1989.
	C106	Brock <i>et al.</i> , "Tumor-Secreted Vascular Permeability Factor Increases Cytosolic Ca ²⁺ and von Willebrand Factor Release in Human Endothelial Cells," <i>Am. J. Path.</i> , 138(1):213-221, 1991.
	C107	Brown <i>et al.</i> , "Leaky Vessels, Fibrin Deposition, and Fibrosis: A Sequence of Events Common to Solid Tumors and to Many Types of Disease," <i>Am. Rev. Respir. Dis.</i> , 140:1104-1107, 1989.
	C109	Clauss <i>et al.</i> , "Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration," <i>J. Exp. Med.</i> , 172:1535-1545, 1990.
	C109	Conn <i>et al.</i> , "Purification of a Glycoprotein Vascular Endothelial Cell Mitogen from a Rat Glioma-Derived Cell Line," <i>Proc. Nat. Acad. Sci. USA</i> , 87:1323-1327, 1990.
	C110	Conn <i>et al.</i> , "Amino Acid and cDNA Sequences of a Vascular Endothelial Cell Mitogen that is Homologous to Platelet-Derived Growth Factor," <i>Proc. Natl. Acad. Sci. USA</i> , 87:2628-2632, 1990.
	C111	Connolly, "Vascular Permeability Factor: A Unique Regulator of Blood Vessel Function," <i>J. Cell Biochem.</i> , 47:219-223, 1991.
	C112	Connolly, "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," <i>J. Clin. Invest.</i> , 84:1470-1478, 1989.
	C113	Denekamp, "Vasculature as a Target for Tumour Therapy," <i>Prog. Appl. Microcirc.</i> , 4:28-38, 1984.
	C114	Dennis and Rifkin, "Studies on the Role of Basic Fibroblast Growth Factor <i>In Vivo</i> : Inability of Neutralizing Antibodies to Block Tumor Growth," <i>J. Cell. Physiol.</i> , 144:84-98, 1990.
	C115	Dvorak <i>et al.</i> , "Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation," <i>Ann. N.Y. Acad. Sci.</i> , 667:101-111, 1992.
	C116	Dvorak, "Leaky Tumor Vessels: Consequences for Tumor Stroma Generation and for Solid Tumor Therapy," <i>Progress in Clinical and Biological Research</i> , 354a: 317-330, 1990.
	C117	Dvorak, "Tumors: Wounds That Do Not Heal," <i>New Eng. J. Med.</i> , 315(26):1650-1659, 1986.
✓	C118	Dvorak <i>et al.</i> , "Regulation of Extravascular Coagulation by Microvascular Permeability," <i>Science</i> , 227:1059-1061, 1985.

EXAMINER:

Catherine J. [Signature]

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified) OCT 07 2004 List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket No. 3999.002587	Serial No. 10/738,404
		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>cf</i>	C119	Dvorak <i>et al.</i> , "Fibrin as a Component of the Tumor Stroma: Origins and Biological Significance," <i>Cancer Metastasis Reviews</i> , 2:41-73, 1983.
	C120	Ferrara <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor Does Not Promote Transformation but Confers a Growth Advantage <i>In Vivo</i> to Chinese Hamster Ovary Cells," <i>J. Clin. Invest.</i> , 91:160-170, 1993.
	C121	Ferrara <i>et al.</i> , "The Vascular Endothelial Growth Factor Family of Polypeptides," <i>J. Cell. Biochem.</i> , 47:211-218, 1991.
	C122	Ferrara and Henzel, "Pituitary Follicular Cells Secrete A Novel Heparin Binding Growth Factor Specific for Vascular Endothelial Cells." <i>Biochem. Biophys. Res. Comm.</i> , 161(2):851-858, 1989.
	C123	Ferrara <i>et al.</i> , "Molecular Characterization and Distribution of Vascular Endothelial Growth Factor," <i>J. Cell Biochem. Supp.</i> , 151(part F):p211, 1991, Abstract No. CF016.
	C124	Folkman and Ingber, "Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:89-96, 1992.
	C125	Folkman and Shing, "Angiogenesis," <i>J. Biol. Chem.</i> , 267(16):10931-10934, 1992.
	C126	Folkman <i>et al.</i> , "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," <i>Nature</i> , 339:58-61, 1989.
	C127	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?," <i>J. Natl. Cancer Inst.</i> , 82(1):4-6, 1990.
	C129	Folkman and Klagsbrun, "Angiogenic Factors," <i>Science</i> , 235:442-447, 1987.
	C129	Gospodarowicz <i>et al.</i> , "Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-Derived Folliculo Stellate Cells," <i>Proc. Natl. Acad. Sci.</i> , 86:7311-7315, 1989.
	C130	Greenblatt and Shubi, "Tumor Angiogenesis: Transfilter Diffusion Studies in the Hamster by the Transparent Chamber Technique," <i>J. Natl. Cancer Inst.</i> , 41:111-124, 1968.
	C131	Houck <i>et al.</i> , "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," <i>Molecular Endocrinology</i> , 5:1806-1814, 1991.
<i>✓</i>	C132	Jain, "Haemodynamic and Transport Barriers to the Treatment of Solid Tumours," <i>Int. J. Radiat. Biol.</i> , 60(1/2):85-100, 1991.

EXAMINER:

Cath. Jones

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C133	Jakeman <i>et al.</i> , "Binding Sites for Vascular Endothelial Growth Factor are Localized on Endothelial Cells in Adult Rat Tissues," <i>J. Clin. Invest.</i> , 89:244-253, 1992.
	C134	Keck <i>et al.</i> , "Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF," <i>Science</i> , 246:1309-1312, 1989.
	C135	Kerbel, "Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents," <i>BioEssays</i> , 13(1):31-36, 1991.
	C136	Leung <i>et al.</i> , "Cloning, Expression During Development, and Evidence for release of a Trophic Factor for Ciliary Ganglion Neurons," <i>Neuron</i> , 8:1045-1053, 1992.
	C137	Leung <i>et al.</i> , "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen," <i>Science</i> , 246:1306-1308, 1989.
	C138	Li <i>et al.</i> , "Monoclonal Antibodies to Recombinant Human Vascular Endothelial Growth Factor (rHuVEGF)," <i>J. Cell. Biochem.</i> , Supp. 15F:251, Abstract CF417, 1991.
	C139	Pepper <i>et al.</i> , "Potent Synergism Between Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in the Induction of Angiogenesis <i>In Vitro</i> " <i>Biochem. Biophys. Res. Comm.</i> , 189(2):824-831, 1992.
	C140	Plate, "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas <i>In vivo</i> ," <i>Nature</i> , 359:845-848, 1992
	C141	Plouet <i>et al.</i> , "Isolation and Characterization of a Newly Identified Endothelial cell Mitogen Produced by AtT-20 Cells," <i>EMBO</i> , 8(12):3801-3806, 1989.
	C142	Roberts and Palade, "Increased Microvascular Permeability and Endothelial Fenestration Induced by Vascular Endothelial Growth Factor," <i>J. Cell Sci.</i> , 108:2369-2379, 1995.
	C143	Senger <i>et al.</i> , "A Highly Conserved Vascular Permeability Factor Secreted by a Variety of Human and Rodent Tumor Cell Lines," <i>Cancer Research</i> , 46:5629-5632, 1986.
	C144	Senger <i>et al.</i> , "Purification and NH ₂ -Terminal Amino Acid Sequence of Guinea Pig Tumor-Secreted Vascular Permeability Factor," <i>Cancer Research</i> , 50:1774-1778, 1990.
	C145	Shweiki <i>et al.</i> , "Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis," <i>Nature</i> , 359:843-845, 1992.
✓	C146	Sioussat <i>et al.</i> , "Anti-Peptide Antibodies to Vascular Permeability Factor," <i>J. Cell Biol.</i> , 115(3 part 2):p264A, Abstract No. 1528, 1991.

EXAMINER:

Cath. [Signature]

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C147	Tischer <i>et al.</i> , "Vascular Endothelial Growth Factor: A New Member of the Platelet-Derived Growth Factor Gene Family," <i>Biochem. Biophys Res. Comm.</i> , 165(3):1198-1206, 1989.
	C148	Van Brugen <i>et al.</i> , "VEGF Antagonism Reduces Edema Formation and Tissue Damage After Ischemia/Reperfusion Injury in the Mouse Brain," <i>J. Clin. Invest.</i> , 104(11):1613-1620, 1999.
	C149	Weidner, "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," <i>New. Eng. J. Med.</i> , 324(1):1-7, 1991.
	C150	Yeo <i>et al.</i> , "Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Guinea Pig and Human Tumor and Inflammatory Effusions," <i>Cancer Research</i> , 53:2912-2918, 1993.
	C151	Yeo <i>et al.</i> , "Development of Time-Resolved Immunofluorometric Assay of Vascular Permeability," <i>Clin. Chem.</i> , 38(1):71-75, 1992.

EXAMINER: <i>Cath</i>	DATE CONSIDERED: <i>3/2/06</i>
-----------------------	--------------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See PageOther Art
See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CF	A65	4,925,922	May 15, 1990	Byers et al.	530	391	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Patth

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A64	5,869,045	Feb. 9, 1999	Hellstrom <i>et al.</i>	424	130.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C98	Wang <i>et al.</i> , "The Effect of Antibody Against Vascular Endothelial Growth Factor on Tumor Growth and Metastasis," <i>J. Can. Res. Clin. Oncol.</i> , 124(11):615-620, 1998 (Abstract only).

EXAMINER:

Catherine Jones

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
cf	C96	Ezzell <i>et al.</i> , "Cancer "Vaccines": An Idea Whose Time Has come?," <i>J. NIH Research</i> , 7:46-49, 1995.
↓	C97	Skolnick <i>et al.</i> , "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," <i>TIBTECH</i> , 18:34-39, 2000.


EXAMINER:

Cathleen Pope

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
3999.002587Serial No.
10/738,404Applicant
Thorpe and BrekkenFiling Date:
December 17, 2003Group:
1642U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page*Other Art
See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>CF</i>	A63	6,703,020	March 9, 2004	Thorpe <i>et al.</i>	424	178.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cathryn Jones

DATE CONSIDERED:

3/2/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404Applicant
Thorpe and BrekkenFiling Date:
December 17, 2003

Group:

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
cf	C95	Thorpe, "Vascular Targeting Agents as Cancer Therapeutics," <i>Clin. Can. Res.</i> , 10:415-427, 2004.

EXAMINER:

Cathleen

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

3999.002587

Serial No.

10/738,404

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Thorpe and Brekken

Filing Date:

December 17, 2003

Group:

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CD	A61	US 2003/0133972A1	July 17, 2003	Danthi <i>et al.</i>	424	450	
↓	A62	US 2003/129223A1	July 10, 2003	Wartchow <i>et al.</i>	424	450	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CD	B17	WO 03/033514 A1	April 24, 2003	PCT			
↓	B18	WO 01/54723 A1	Aug. 2, 2001	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Catherine J. [Signature]

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

3999.002587

10/738,404

List of Patents and Publications for Applicant's

Applicant

Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

December 17, 2003

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CF	A60	US 2003/0194400 A1	Oct. 16, 2003	Liu <i>et al.</i>	424	94.64	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CF	B16	WO 03/035688 A2	May 1, 2003	PCT			


Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003

Group:

U.S. Patent Documents
See Page 1Foreign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A59	5,057,313	October 15, 1991	Shih <i>et al.</i>	424	85.91	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C94	Hardman <i>et al.</i> , In Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition, pages 51 and 57-58, 1996.

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

JAN 28 2004

Atty. Docket No.

3999.002587

Serial No.

10/738,404

List of Patents and Publications for Applicant

Applicant

Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

December 17, 2003

Group:

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)


Exam. Init.	Ref. Des.	Citation
cf	C88	De Bandt <i>et al.</i> , "Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI) but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis," <i>J. Immunol.</i> , 171:4853-4859, 2003.
	C89	LeCouter <i>et al.</i> , "Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1," <i>Science</i> , 299:890-893, 2003
	C90	Maes <i>et al.</i> , "Soluble VEGF Isoforms are Essential for Establishing Epiphyseal Vascularization and Regulating Chondrocyte Development and Survival," <i>J. Clin. Invest.</i> , 113:188-199, 2004.
	C91	Pipp <i>et al.</i> , "VEGFR-1-Selective VEGF Homologue PlGF is Arteriogenic Evidence for a Monocyte-Mediated Mechanism," <i>Circ. Res.</i> , 92:1-9, 2003.
	C92	Qi <i>et al.</i> , "A Novel Function for Tissue Inhibitor of Metalloproteinases-3 (TIMP3): Inhibition of Angiogenesis by Blockage of VEGF Binding to VEGF Receptor-2," <i>Nature Medicine</i> , 9(4):407-415, 2003.
	C93	Shih <i>et al.</i> , "Selective Stimulation of VEGFR-1 Prevents Oxygen-Induced Retinal Vascular Degeneration in Retinopathy of Prematurity," <i>J. Clin. Invest.</i> , 112:50-57, 2003.

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.

3999.002587

Serial No.

10/738,404

List of Patents and Publications for Applicant's

Applicant

Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

December 17, 2003

Group:

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page

Other Art

See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CS	A59	6,676,941	Jan. 13, 2004	Thorpe <i>et al.</i>	424	178.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cathleen Ayre

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A1	6,093,399	July 25, 2000	Thorpe <i>et al.</i>	424	182	
	A2	6,051,230	April 18, 2000	Thorpe <i>et al.</i>	424	178.1	
	A3	6,036,955	March 14, 2000	Thorpe <i>et al.</i>	424	136.1	
	A4	6,022,541	February 8, 2000	Senger <i>et al.</i>	424	172.1	
	A5	6,004,555	December 21, 1999	Thorpe <i>et al.</i>	424	181.1	
	A6	6,004,554	December 21, 1999	Thorpe <i>et al.</i>	424	178.1	
	A7	5,965,132	October 12, 1999	Thorpe <i>et al.</i>	424	149	
	A8	5,877,289	March 2, 1999	Thorpe <i>et al.</i>	530	387.1	
	A9	5,874,542	February 23, 1999	Rockwell <i>et al.</i>	530	387.3	
	A10	5,874,081	February 23, 1999	Parish	424	130.1	
	A11	5,866,127	February 2, 1999	Senger <i>et al.</i>	424	178.1	
	A12	5,863,538	January 26, 1999	Thorpe <i>et al.</i>	424	136.1	
	A13	5,855,866	January 5, 1999	Thorpe <i>et al.</i>	424	1.49	
	A14	5,854,205	December 29, 1998	O'Reilly <i>et al.</i>	514	2	
	A15	5,840,301	November 24, 1998	Rockwell <i>et al.</i>	424	143.1	
	A16	5,776,427	July 7, 1998	Thorpe <i>et al.</i>	424	1.49	
	A17	5,677,181	October 14, 1997	Parish	435	332	
	A18	5,660,827	August 26, 1997	Thorpe <i>et al.</i>	424	152.1	
	A19	5,659,013	August 19, 1997	Senger <i>et al.</i>	530	350	
	A20	5,587,297	December 24, 1996	Jacobson <i>et al.</i>	435	29	
	A21	5,569,786	October 29, 1996	Pettit <i>et al.</i>	568	646	
	A22	4,975,278	December 4, 1990	Senter <i>et al.</i>	424	94.3	
	A23	4,940,726	July 10, 1990	Pettit <i>et al.</i>	514	450	

EXAMINER: Cath

DATE CONSIDERED: 3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A24	4,456,550	June 26, 1984	Dvorak <i>et al.</i>	260	112	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CJ	B1	WO99/40118	Aug. 12, 1999	PCT			
	B2	WO 98/45332	Oct. 15, 1998	PCT			
	B3	WO 98/45331	Oct. 15, 1998	PCT			
	B4	WO 96/01653	Jan. 25, 1996	PCT			
	B5	WO 93/17715	Sept. 16, 1993	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C1	Akuzawa, <i>et al.</i> , "Zinc Finger Transcription Factor Egr-1 Activates Flt-1 Gene Expression in THP-1 Cells on Induction for Macrophage Differentiation", <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 20(2):377-84, 2000.
	C2	Asano, <i>et al.</i> , "Inhibition of Tumor Growth and Metastasis by an Immunoneutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor/Vascular Permeability Factor," <i>Cancer Res.</i> , 55:5296-5301, 1995.
	C3	Asano, <i>et al.</i> , "An Anti-human VEGF Monoclonal Antibody, MV833, that Exhibits Potent Anti-tumor Activity <i>in vivo</i> ," <i>Hybridoma</i> , 17:185-90, 1998.
	C4	Baca <i>et al.</i> , "Antibody Humanization using Monovalent Phage Display," <i>J. Biol. Chem.</i> , 272(16):10678-84, 1997.
	C5	Benjamin, <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
	C6	Borgstrom, <i>et al.</i> , "Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy," <i>Cancer Res.</i> , 56(17):4032-1439, 1996.

EXAMINER:

Cath Anne

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
ef	C7	Borgstrom, <i>et al.</i> , "Neutralizing Anti-vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>in vivo</i> ," <i>Prostate</i> , 35(1):1-10, 1998.
	C8	Borgstrom, <i>et al.</i> , "Importance of VEGF for Breast Cancer Angiogenesis <i>in vivo</i> : Implications from Intravital Microscopy of Combination Treatments with an Anti-VEGF Neutralizing Monoclonal Antibody and Doxorubicin," <i>Anticancer Research</i> , 19(5B):4203-11, 1999.
	C9	Brekken, "Vascular Endothelial Growth Factor as a Target for the Therapy of Solid Tumors," <i>Ph.D. Dissertation, The University of Texas Southwestern Medical Center at Dallas</i> , February, 1999; Volume 60104-B of Dissertation Abstracts International, page 1385.
	C10	Brekken, <i>et al.</i> , "Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium," <i>Cancer Res.</i> , 58(9):1952-1959, 1998.
	C11	Burrows and Thorpe, "Vascular Targeting-a New Approach to the Therapy of Solid Tumors," <i>Pharmacol. Ther.</i> , 64:155-174, 1994.
	C12	Burrows <i>et al.</i> , "A Murine Model for Antibody-Directed Targeting of Vascular Endothelial Cells in Solid Tumors," <i>Cancer Research</i> , 52:5954-5962, 1992.
	C13	Burrows and Thorpe, "Eradication of Large Solid Tumors in Mice with an Immunotoxin Directed Against Tumor Vasculature," <i>Proc. Natl. Acad. Sci. USA</i> , 90:8996-9000, 1993.
	C14	Claffey, <i>et al.</i> , "Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor by Melanoma Cells Increases Tumor Growth, Angiogenesis, and Experimental Metastasis," <i>Cancer Res.</i> , 56:172-181, 1996.
	C15	Clauss <i>et al.</i> , "The Vascular Endothelial Cell Growth Factor Receptor Flt-1 Mediates Biological Activities," <i>J. Biol. Chem.</i> , 271(30):17629-17634, 1996.
	C16	Davis and Yancopoulos, "The Angiopoietins: Yin and Yang in Angiogenesis", <i>Curr. Top. Microbiol. Immunol.</i> , 237:173-85, 1999.
	C17	Denekamp, "Vascular Attack as a Therapeutic Strategy for Cancer," <i>Cancer and Metastasis Reviews</i> , 9:267-282, 1990.
	C18	Dvorak <i>et al.</i> , "Structure of Solid Tumors and Their Vasculature: Implications for Therapy with Monoclonal Antibodies," <i>Cancer Cells</i> , 3:77-85, 1991.
	C19	Dvorak, <i>et al.</i> , "Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors - Concentration in Tumor Blood Vessels," <i>J. Exp. Med.</i> , 174:1275-1278, 1991.
	C20	Fidler and Ellis, "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis [comment]," <i>Cell</i> , 79(2):185-188, 1994.

EXAMINER:

Cuth Jm

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CP	C21	Fong, <i>et al.</i> , "Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium," <i>Nature</i> , 376:66-70, 1995.
	C22	Gerber, <i>et al.</i> , "VEGF Couples Hypertrophic Cartilage Remodeling, Ossification and Angiogenesis During Endochondral Bone Formation"; <i>Nature Medicine</i> , 5(6):623-8, 1999.
	C23	Hagemeier <i>et al.</i> , "A Monoclonal Antibody Reacting with Endothelial Cells of Budding Vessels in Tumors and Inflammatory Tissues, and Non-Reactive with Normal Adult Tissues," <i>Int. J. Cancer</i> , 38:481-488, 1986.
	C24	Hanahan and Folkman, "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):353-364, 1996.
	C25	Hiratsuka, <i>et al.</i> , "Flt-1 Lacking the Tyrosine Kinase Domain is Sufficient for Normal Development and Angiogenesis in Mice," <i>Proc. Natl. Acad. Sci. USA</i> , 95(16):9349-9354, 1998.
	C26	Holash <i>et al.</i> , "Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF", <i>Science</i> , 284:1994-1998, 1999.
	C27	Huang <i>et al.</i> , "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Science</i> , 275:547-550, 1997.
	C28	Keyt <i>et al.</i> , "Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors. Generation of Receptor-Selective VEGF Variants by Site-Directed Mutagenesis," <i>J. Biol. Chem.</i> , 271(10):5638-46, 1996.
	C29	Kim, <i>et al.</i> , "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies," <i>Growth Factors</i> , 7:53-64, 1992.
	C30	Kim, <i>et al.</i> , "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth <i>in vivo</i> ," <i>Nature</i> , 362:841-844, 1993.
	C31	Kondo, <i>et al.</i> , "Significance of Vascular Endothelial Growth Factor/Vascular Permeability Factor for Solid Tumor Growth, and its Inhibition by the Antibody," <i>Biochem. Biophys. Res. Commun.</i> , 194:1234-1241, 1993.
	C32	Koukourakis, <i>et al.</i> , "Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer," <i>Cancer Res.</i> , 60:3088-3095, 2000.
	C33	Kroll and Waltenberger, "The Vascular Endothelial Growth Factor Receptor KDR Activates Multiple Signal Transduction Pathways in Porcine Aortic Endothelial Cells", <i>J. Biol. Chem.</i> , 272:32521-7, 1997.
	C34	Lin, <i>et al.</i> , "Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor", <i>J. Pharmacol. Exp. Therap.</i> , 288(1):371-8, 1999.

EXAMINER:

Cuth [Signature]

DATE CONSIDERED:

3/2/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C35	Lin-Ke, <i>et al.</i> , "Vascular Targeting of Solid and Ascites Tumors with Antibodies to Vascular Endothelial Growth Factor," <i>Eur. J. Cancer</i> , 32A(14):2467-2473, 1996.
	C36	Luo, <i>et al.</i> , "Differential Inhibition of Fluid Accumulation and Tumor Growth in Two Mouse Ascites Tumors by an Antivascular Endothelial Growth Factor/Permeability Factor Neutralizing Antibody," <i>Cancer Res.</i> , 58(12):2594-2600, 1998.
	C37	Luo, <i>et al.</i> , "Significant Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Mouse Ascites Tumors," <i>Cancer Res.</i> , 58(12):2652-2660, 1998.
	C38	Mesiano, <i>et al.</i> , "Role of Vascular Endothelial Growth Factor in Ovarian Cancer: Inhibition of Ascites Formation by Immunoneutralization," <i>Am. J. Pathol.</i> , 153(4):1249-1256, 1998.
	C39	Mordenti, <i>et al.</i> , "Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans", <i>Toxicologic Pathology</i> , 27(1):14-21, 1999.
	C40	Muller, <i>et al.</i> , "VEGF and the Fab Fragment of a Humanized Neutralizing Antibody: Crystal Structure of the Complex at 2.4 Å Resolution and Mutational Analysis of the Interface," <i>Structure</i> , 6(9):1153-67, 1998.
	C41	Mustonen and Alitalo, "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis," <i>J. Cell Biol.</i> , 129:895-898, 1995.
	C42	Niida, <i>et al.</i> , "Vascular Endothelial Growth Factor can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption", <i>J. Exp. Med.</i> , 190(2):293-8, 1999.
	C43	Ohizumi <i>et al.</i> , "Antibody-Based Therapy Targeting Tumor Vascular Endothelial Cells Suppresses Solid Tumor Growth in Rats," <i>Biochem. Biophys. Res. Comm.</i> , 236:493-496, 1997.
	C44	Presta, <i>et al.</i> , "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and other Disorders," <i>Cancer Res.</i> , 57:4593-4599, 1997.
	C45	Ran <i>et al.</i> , "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," <i>Cancer Res.</i> , 58:4646-4653, 1998.
	C46	Ruf and Edgington, "Structural Biology of Tissue Factor, the Initiator of Thrombogenesis <i>in vivo</i> ," <i>FASEB J.</i> , 8: 385-390, 1994.
✓	C47	Ryan, <i>et al.</i> , "Preclinical Safety Evaluation of rhuMabVEGF, an Antiangiogenic Humanized Monoclonal Antibody", <i>Toxicologic Pathology</i> , 27(1):78-86, 1999.

EXAMINER:



DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1 and 2	Foreign Patent Documents See Page 2	Other Art See Page 2-6	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C48	Schlaeppli and Wood, "Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-Tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-Kinase Inhibitors," <i>Cancer and Metastasis Rev.</i> , 18:473-481, 1999.
	C49	Shalaby, <i>et al.</i> , "Failure of Blood-Island Formation and Vasculogenesis in Flk-1-Deficient Mice," <i>Nature</i> , 376:62-66, 1995.
	C50	Siemeister, <i>et al.</i> , "The Pivotal Role of VEGF in Tumor Angiogenesis: Molecular Facts and Therapeutic Opportunities," <i>Cancer Metastasis Rev.</i> , 17(2):241-248, 1998.
	C51	Sioussat, <i>et al.</i> , "Inhibition of Vascular Permeability Factor (Vascular Endothelial Growth Factor) with Antipeptide Antibodies," <i>Arch. Biochem. Biophys.</i> , 301:15-20, 1993.
	C52	Veikkola, <i>et al.</i> , "Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors," <i>Cancer Res.</i> , 60-203-212, 2000.
	C53	Waltenberger, <i>et al.</i> , "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> , 269(43):26988-26995, 1994.
	C54	Wiesmann, <i>et al.</i> , "Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor," <i>Cell</i> , 91(5):695-704, 1997.
	C55	Co-pending Application Serial No. 09/561,500; Entitled: "Antibody Compositions for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket Nos. 4001.002500).
	C56	Co-pending Application Serial No. 09/561,499; Entitled: "Antibody Methods for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket Nos. 4001.002582)
	C57	Co-pending Application Serial No. 09/562,245; Entitled: "Antibody Kits for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket No. 4001.002583).
	C58	Co-pending Application Serial No. 09/561,108; Entitled: "Antibody Conjugate Compositions for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket No. 3999.002584).
	C59	Co-pending Application Serial No. 09/561,526; Entitled: "Antibody Conjugate Kits for Selectively Inhibiting VEGF"; filed April 28, 2000 (Attorney Docket No. 3999.002586).

EXAMINER: Catharine Jones	DATE CONSIDERED: 3/2/06
---------------------------	-------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C60	Deonarain and Epenetos, "Targeting Enzymes for Cancer Therapy: Old Enzymes in New Roles," <i>Br. J. Cancer</i> , 70(5):786-794, 1994.
	C61	Giorgio <i>et al.</i> , "Ellipticine Conjugated to Anti VEGFR2 Monoclonal Antibodies as Reagents for Targeting angiogenesis," <i>Proc. Amer. Assoc. Can. Ann.</i> , 41:387, 2000.
	C62	Haisma <i>et al.</i> , "Analysis of a Conjugate between Anti-Carcinoembryonic Antigen Monoclonal Antibody and Alkaline Phosphatase for specific Activation of the Prodrug Etoposide Phosphate," <i>Cancer Immunol. Immunother.</i> , 34(5):343-348, 1992.
	C63	Huber <i>et al.</i> , "Vascular Endothelial Growth Factor Receptor (VEGFR-2) Antibody Therapy Combined with Conventional Chemotherapy Inhibits Growth of Established Tumors in Mice," <i>Proc. Amer. Assoc. Cancer Res. Ann.</i> , 41:567, 2000.
	C64	Muller <i>et al.</i> , "Vascular Endothelial Growth Factor: Crystal Structure and Functional Mapping of the Kinase Domain Receptor Binding Site," <i>Proc. Natl. Acad. Sci. USA</i> , 94(14):7192-7197, 1997.
	C65	Ortega <i>et al.</i> , "Signal Relays in the VEGF System," <i>Frontiers in Bioscience</i> , 4:D141-152, 1999.
	C66	Witte <i>et al.</i> , "Monoclonal Antibodies Targeting the VEGF Receptor-2 (Flk1/KDR) as an Anti-Angiogenic Therapeutic Strategy," <i>Cancer and Metastasis Reviews</i> , 17(2):155-161, 1998.
	C67	International Search Report for PCT/US00/11367, mailed October 19, 2000.

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page	Other Art See Page	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>ej</i>	A25	5,521,073	05.28.96	Davis <i>et al.</i>	435	69.5	
<i>ej</i>	A26	5,643,755	07.01.97	Davis <i>et al.</i>	435	69.5	
	A27	5,650,490	07.22.97	Davis <i>et al.</i>	530	350	
	A28	5,814,464	09.29.98	Davis <i>et al.</i>	435	69.5	
	A29	5,851,797	12.22.98	Valenzuela <i>et al.</i>	435	69.1	
	A30	5,879,672	03.09.99	Davis <i>et al.</i>	424	85.1	
	A31	5,972,338	10.26.99	Godowski <i>et al.</i>	424	185.1	
	A32	6,030,831	02.29.00	Godowski <i>et al.</i>	435	320.1	
	A33	6,057,435	05.02.00	Godowski <i>et al.</i>	536	23.5	
<i>✓</i>	A34	6,074,873	06.13.00	Fong <i>et al.</i>	435	325	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Colthorn

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
----------------	--------------	--------------------	------	------	-------	--------------	------------------------

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>CD</i>	C68	Kuby, "Antigens", <i>Immunology, Second Edition, Chapter 4</i> , 85-96, 1994.
<i>W</i>	C69	Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662, 1991.

EXAMINER:

Cathleen

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CJ	A35	5,354,778	October 11, 1994	Ray <i>et al.</i>	514	592	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CJ	C70	Heimbrook <i>et al.</i> , "Transforming growth factor α - <i>Pseudomonas</i> exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts," <i>Proc. Natl. Acad. Sci. USA</i> , 87:4697-4701, 1990.
	C71	Hirota <i>et al.</i> , "Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody," <i>Cancer Research</i> , 49:7106-7109, 1989.
✓	C72	Plate <i>et al.</i> , "Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis," <i>Cancer Research</i> , 53(23):5822-5827, 1993.

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>CP</i>	A36	5,786,344	July 28, 1998	Ratain et al.	514	100	
<i>J</i>	A37	5,561,122	October 1, 1996	Pettit	514	130	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Canth *Qm*

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1643
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>CO</i>	B6	WO 95/21868	August 17, 1995	PCT			
	B7	WO 94/11499	May 26, 1994	PCT			
	B8	WO 94/10202	May 11, 1994	PCT			
<i>✓</i>	B9	WO 92/14748	September 3, 1992	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cathleen D...

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket N . 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>CD</i>	B10	WO 93/08210	April 29, 1993	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>CD</i>	C73	Denekamp, "Endothelial Cell Attack as a Novel Approach to Cancer Therapy," <i>Cancer Topics</i> , 6:6-8, 1986.
<i>↓</i>	C74	Denekamp, The Current Status of Targeting Tumor Vasculature as a Means of Cancer Therapy: An Overview," <i>Int. J. Radiat. Biol.</i> , 60:401-408, 1991.

EXAMINER:

Conth Dwyer

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>CJ</i>	C75	Supplemental European Search Report for Divisional Application 01125821.7, mailed December 27, 2001.

EXAMINER:

Cathryn Dwyer

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>CP</i>	A38	6,342,221	January 29, 2002	Thorpe & Brekken	424	178.1	
<i>↓</i>	A39	6,342,219	January 29, 2002	Thorpe & Brekken	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cathleen

DATE CONSIDERED:

3/2/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. D cket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Th rpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CF	A40	5,024,834	June 18, 1991	Houston <i>et al.</i>	424	85.91	
	A41	4,981,953	January 1, 1991	Barbieri <i>et al.</i>	530	391	
	A42	4,980,457	December 25, 1990	Jansen <i>et al.</i>	530	391	
✓	A43	4,958,009	September 18, 1990	Bjorn <i>et al.</i>	530	389	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CF	B11	WO 91/07941	June 13, 1991	PCT			
✓	B12	EP 0 255 424 A1	February 3, 1988	EPO			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cathleen Olsen

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002585Serial No.
09/561,005

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
April 28, 2000Group:
1642U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CP	A44	6,291,667	Sept. 18, 2001	Gill <i>et al.</i>	536	24.5	
	A45	6,121,230	Sept. 19, 2000	Charnock-Jones <i>et al.</i>	514	2	
	A46	6,024,955	Feb. 15, 2000	Asano <i>et al.</i>	424	130.1	
	A47	6,020,473	Feb. 01, 2000	Keyt <i>et al.</i>	536	23.1	
	A48	6,008,319	Dec. 28, 1999	Epstein <i>et al.</i>	530	324	
	A49	6,007,817	Dec. 28, 1999	Epstein <i>et al.</i>	424	178.1	
	A50	5,942,385	Aug. 24, 1999	Hirth	435	4	
	A51	5,730,977	March 24, 1998	Ooka <i>et al.</i>	424	141.1	
	A52	5,240,848	Aug. 31, 1993	Keck <i>et al.</i>	537	240.2	
	A53	5,036,003	July 30, 1991	Olander <i>et al.</i>	435	70.1	
	A54	5,008,196	April 16, 1991	Connolly <i>et al.</i>	435	240.2	
	A55	2002/0032315	March 14, 2002	Baca <i>et al.</i>	530	388.23	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
CP	B13	EP 0 666 868 B1	April 03, 2002	EPO			
	B14	WO 00/37502	June 29, 2000	PCT			
	B15	WO 00/34337	June 15, 2000	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1644
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CP	A56	6,416,758	July 9, 2002	Thorpe <i>et al.</i>	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cath Jm

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
CG	A57	6,180,370	January 30, 2001	Queen <i>et al.</i>	435	69.6	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CG	C76	Bodey <i>et al.</i> , "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Res.</i> , 20:2665-2676, 2000.
↓	C77	Colman, "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions," <i>In A Structural View of Immune Recognition by Antibodies</i> , 33-36, 1994.
↓	C78	Spitler, "Cancer Vaccines: The Interferon Analogy," <i>Cancer Biotherapy</i> , 10(1):1-3, 1995.

EXAMINER: <i>Cuth</i>	DATE CONSIDERED: <i>3/2/06</i>
-----------------------	--------------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C79	Abaza and Atassi, "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <i>J. Protein Chemistry</i> , 11(5):433-444, 1992
	C80	Attwood, "The Babel of Bioinformatics," <i>Science</i> , 290(5491):471-473, 2000.
	C81	Mikayama <i>et al.</i> , "Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor," <i>Proc. Natl. Acad. Sci. USA</i> , 90:10056-10060, 1993.
	C82	Ngo <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>In, The Protein Folding Problem and Tertiary Structure Prediction</i> , Eds., Merz & LeGrand, pp. 492-495, 1994.
	C83	Voet <i>et al.</i> , "Chemical Evolution," <i>In, Biochemistry I</i> , Voet & Voet, pp. 126-234, 1990.

EXAMINER:

DATE CONSIDERED:

3/2/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents <i>See Page</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Page 1</i>	





U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.


Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C84	Connolly <i>et al.</i> , "Human Vascular Permeability Factor," <i>J. Biol. Chem.</i> , 264(33):20017-20024, 1989.
	C85	Ferrara <i>et al.</i> , "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins," <i>Endocrine reviews</i> , 13(1):18-32, 1992.
	C86	Hori <i>et al.</i> , "Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody Against Human Basic Fibroblast Growth Factor," <i>Cancer Res.</i> , 51:6180-6184, 1991.
	C87	Takahashi <i>et al.</i> , "Inhibition of Cell Growth and Tumorigenesis of Human Glioblastoma Cells by a Neutralizing Antibody Against Human Basic Fibroblast Growth Factor," <i>FEBS Lett.</i> , 288(1,2):65-71, 1991.

EXAMINER:



DATE CONSIDERED:

3/2/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002585	Serial No. 09/561,005
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: April 28, 2000	Group: 1642
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page	Other Art See Page	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>CP</i>	A58	6,524,583	February 25, 2003	Thorpe <i>et al.</i>	424	145.1	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

EXAMINER:

Cath Jones

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

Filing Date:
December 17, 2003Group:
1642

(Use several sheets if necessary)

U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Pages 1


U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C152	Ben-Hur and Orenstein, "The Endothelium and Red Blood Cell as Potential Targets in PDT-Induced Vascular Stasis," <i>J. Radiat. Biol.</i> , 60(1/2):293-301, 1991.
	C153	Folkman, "Tumor Angiogenesis," <i>Adv. Cancer Res.</i> , 43:175-203, 1985.
	C154	Gschwind <i>et al.</i> , "The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy," <i>Nature Reviews/Cancer</i> , 4:361-370, 2004.
	C155	Martiny-Baron and Marmé, "VEGF-Mediated Tumour Angiogenesis: A New Target for Cancer Therapy," <i>Curr. Opin. Biotech.</i> , 6:675-680, 1995.
	C156	McDonald and Baluk, "Significance of Blood Vessel Leakiness in Cancer," <i>Cancer Research</i> , 62:5381-5385, 2002.
	C157	Murata <i>et al.</i> , "Immunohistochemical Detection of Extravasated Fibrinogen (Fibrin) in Human Diabetic Retina," <i>Graefe's Arch. Clin. Exp. Ophthalmol.</i> , 230:428-431, 1992.
	C158	Risau, "What, if anything, is an Angiogenic Factor?" <i>Cancer Metastasis Rev.</i> , 15:149-151, 1996.
	C159	Senger <i>et al.</i> , "Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid," <i>Science</i> , 219:983-985, 1983.
	C160	Sioussat <i>et al.</i> , "Inhibition of Vascular Permeability Factor (Vascular Endothelial Growth Factor) with Antipeptide Antibodies," <i>Arch. Biochem. Biophys.</i> , 301(1):15-20, 1993.
	C161	Wiig <i>et al.</i> , "Interstitial Fluid Pressure in DMBA-Induced Rat Mammary Tumours," <i>Scand. J. Clin. Lab. Invest.</i> , 42:159-164, 1982.


EXAMINER:



DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.
3999.002587Serial No.
10/738,404

List of Patents and Publications for Applicant's

Applicant
Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 17, 2003Group:
1642U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.


Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CF	C162	Fishman <i>et al.</i> , "Autoimmunity and Cancer - Beneficial Relationships: A New Concept for the Production of Human Monoclonal Antibodies (Review)," <i>Int. J. Oncol.</i> , 10:901-904, 1997.
↓	C163	Tschmelitsch <i>et al.</i> , "Enhanced Antitumor Activity of Combination Radioimmunotherapy (¹³¹ I-Labeled Monoclonal Antibody A33) with chemotherapy (Fluorouracil)," <i>Cancer Res.</i> , 57:3181-3186, 1997.

EXAMINER:



DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
3999.002587Serial No.
10/738,404Applicant
Thorpe and BrekkenFiling Date:
December 17, 2003Group:
1642U.S. Patent Documents
See PageForeign Patent Documents
See PageOther Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
CP	C164	Stephan <i>et al.</i> , "Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer," <i>Clin. Can. Res.</i> , 10:6993-7000, 2004.

EXAMINER:

Cath Jpn

DATE CONSIDERED:

3/2/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.